Lv53
1250 积分 2022-02-16 加入
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC‒A Brief Report
19小时前
求助中
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC – A Brief Report
2天前
求助中
MAPK inhibition in BRAF(V600E) CRC
14天前
已完结
A new first-line standard-of-care for BRAF(V600E)-mutated mCRC
15天前
已完结
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
18天前
已完结
A new first-line standard-of-care for BRAF(V600E)-mutated mCRC
18天前
已完结
Tunlametinib: First Approval
1个月前
已完结
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
1个月前
已完结
BRAF - a tumour-agnostic drug target with lineage-specific dependencies
1个月前
已完结
Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
4个月前
已完结
皖公网安备34019202002308
